Floatz logo

Gdc-0449

Recurrent Pancreatic Carcinoma

OHSU Knight Cancer InstitutePhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

103 Active assets in the Recurrent Pancreatic Carcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
OHSU Knight Cancer Institute
Phase 2/3BBB
Irinotecan
OHSU Knight Cancer Institute
Phase 2/3BBB
FLUOROURACILUM
Northwestern University
Phase 2/3BBB
Capecitabine
Zhejiang University
Phase 2BB
Vinorelbine
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Gdc-0449 is also rated in:

malignant pancreatic neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
adult glioblastomaDormant
BB
Indicative ·
65 / 100
View asset →
breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →